A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 275, 120986
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
This publication has 43 references indexed in Scilit:
- Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapyThe Lancet Respiratory Medicine, 2020
- Pulmonary fibrosis secondary to COVID-19: a call to arms?The Lancet Respiratory Medicine, 2020
- Tissue damage from neutrophil-induced oxidative stress in COVID-19Nature Reviews Immunology, 2020
- Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic interventionToxicology Reports, 2020
- The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotypeEuropean Respiratory Review, 2018
- Efferocytosis of apoptotic alveolar epithelial cells is sufficient to initiate lung fibrosisCell Death & Disease, 2018
- Macrophages: friend or foe in idiopathic pulmonary fibrosis?Respiratory Research, 2018
- Bilirubin Nanoparticles as a Nanomedicine for Anti‐inflammation TherapyAngewandte Chemie International Edition, 2016
- Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signalingProceedings of the National Academy of Sciences, 2015
- Oxidative stress and pulmonary fibrosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013